Management of High Disease Activity in Multiple Sclerosis Using Zytux<sup>TM</sup> (Rituximab, AryoGen Pharmed): Evidence from a Case Report
| Author | Abdorreza Naser Moghadasi | en |
| Author | Esmaeil Ghoreyshi Tayyebi | en |
| Orcid | Abdorreza Naser Moghadasi [0000-0002-8598-0911] | en |
| Issued Date | 2020-04-27 | en |
| Abstract | Rituximab is an anti-CD20 monoclonal antibody, which is used for the treatment of various autoimmune diseases. Owing to its marked effect on B cells, rituximab has also been used in the treatment of fulminant multiple sclerosis. The present study aimed to describe the case of a patient with fulminant radiological presentation, which was effectively controlled using rituximab. A 21-year-old woman initially presented with vertigo, which resolved spontaneously. The MRI indicated extensive periventricular involvement with multiple enhancing lesions. The patient was hospitalized and received pulse methylprednisolone (1 g) daily for five days. Afterwards, she was administered with ZytuxTM (1 g; rituximab, AryoGen Pharmed) for two weeks. | en |
| DOI | https://doi.org/10.5812/jkums.101422 | en |
| Keyword | Zytux<sup>TM</sup> | en |
| Keyword | Rituximab | en |
| Keyword | Highly Active Multiple Sclerosis | en |
| Keyword | MRI | en |
| Publisher | Brieflands | en |
| Title | Management of High Disease Activity in Multiple Sclerosis Using Zytux<sup>TM</sup> (Rituximab, AryoGen Pharmed): Evidence from a Case Report | en |
| Type | Case Report | en |